Abstract
Liver fibrosis is a dynamic pathological condition which can be slowed down in its initial phases. Without proper clinical management of fibrosis, progressive liver damage may lead to cirrhosis and ultimately to liver failure or primary liver cancer, which are irreversible conditions. Therefore, in order to cure fibrotic damage to liver, its early stages should be the centre of attention. In this context, some supplements and ‘complementary and alternative medicine (CAM)’ deserve specific mention, because of their already recognized natural way of healing and long lasting curative effects. Moreover, CAM display negligible side effects and hence it is gaining worldwide importance in clinical practices. In particular, herbal medicines are now replacing synthetic pharmaceuticals and looked upon as the sources of novel bioactive substances. To develop satisfactory herbal combinations for treating liver fibrosis, phytoproducts need to be systematically evaluated for their potency as anti-fibrotic, anti-hepatotoxic and antioxidant agents. More importantly, the identified herb/agent should have the remarkable tendency to stimulate hepatocytes regeneration. The present review is a systematic account of at least fifty medicinal herbs and their products which in experimental models have demonstrated antifibrotic activity and thus, most likely candidates to offer therapeutic protection to liver. Nevertheless, much additional work is still needed to explore molecular pathways to discover potential applications of these medicines so as to open up new vistas in biomedical research.
Keywords: Liver fibrosis, Herbal medicine, Phytoproducts, Complementary and alternative medicine, Hepatoprotection
Graphical abstract
Schematic representation of active ingredients of phyto-medicine used in the treatment of liver fibrosis.
1. Introduction
Liver is one of the most important organs that plays crucial roles in the physiological functions of our body.1, 2 In human body liver is the site of regulation of glycogen storage, decomposition of RBCs, hormone and plasma protein production and detoxification.3 Since liver also plays a central role in detoxifying and transforming chemicals, it is in a way exposed to their harmful effects increasing its susceptibility to diseases. Therefore, it may not be surprising that over 10% of the world population suffers from liver diseases. Most common of these conditions are hepatitis, hepatic steatosis (fatty liver), fibrosis, cirrhosis, alcoholic and drug induced diseases.4 Synthetic drugs used to treat liver ailments have often proved life threatening and therefore, the preference is being shifted to complementary and alternative medicines (CAM), which are either natural products or their derivatives. The very basis of this preference is their safety and long lasting therapeutic potential. As a result, the source of nearly half of the agents used to treat liver diseases now come from natural products. Available evidence further indicates that bioactive compounds derived from medicinal herbs may be potential hepatoprotective agents. Out of the broad range of natural products, herbal medication plays a fundamental role, since 65% of patients in Europe and US depend on herbal remedies for the treatment of liver diseases.4 However, their preparation, search and extraction is an exhaustive procedure. (see Fig. 1, Fig. 2)
Fig. 3.
Schematic representation of the biochemical characterization of active phyto-ingredients.
Fig. 1.
Flow chart representing the general process of preparation of plant extract.
Fig. 2.
Representation of the systematic process followed to search a bioactive compound from herb.
Of all liver ailments, fibrosis has emerged as a major health concern. It is the consequences of sustained wound healing response to a chronic liver injury from a variety of causes including viral, autoimmune, drug induced, cholestatic and metabolic diseases. Hepatic fibrosis is characterized by immoderate production and deposition of extracellular matrix (ECM).5, 6, 7, 8 Activated hepatic stellate cells (HSCs), portal fibroblasts and myofibroblasts of bone marrow origin have been identified as the major collagen producing cells.9 If left uncured, fibrosis can lead to cirrhosis and ultimately to hepatocellular carcinoma which are irreversible. Mortality statistics raises the level of concern further, since as compared to 0.8 million deaths in 199010, cirrhosis resulted in 1.2 million deaths in 2013. Hepatocellular carcinoma (HCC) is the fifth most common cancer with more than 1 million annual mortality worldwide.11 Hepatocellular carcinoma is less common in most parts of the developed western world but appears to be markedly increasing in Asian countries.12 Thus, there is an urgent need to investigate the causes and remedies for hepatic fibrosis so as to procure normal liver function.
Complementary and alternative medicine (CAM) is used in medical treatment but it is not the component of mainstream medicine system. Extensive use of CAM is highlighted among people with chronic diseases, since it helps to avoid malaise often associated with conventional health care and empower people to manage their chronic condition.13 Complementary and alternative medicine is classified by National Center for Complementary and Alternative Medicine (NCCAM), USA into five categories: whole medical system, mind body medicine, manipulative and body based practices, energy medicine and biologically based practices. On record, biologically-based practices such as herbal remedies continue to play highly significant role in health care. About 80% of the world's population relies mainly on CAM, especially herbal medication, for their primary health care.14 The use of phytomedicine perhaps began in China at the time of Xia dynasty and in India during Vedic times. Herbal remedies are rejoicing growing popularity throughout the world because of many reasons like long lasting curative effects, efficacy, safety, natural way of healing and lesser side effects.15, 16 Treatment with medicinal herbal-concentrates fortifies natural healing process and adds to feeling of wellness.17A number of herbal derivatives show promising effects against hepatic fibrosis either experimentally in cell culture (in vitro), in animals models (in vivo) or even in clinical trials. In this review, we have systematically presented published information that describes the mechanism of attenuation of liver fibrosis in experimental models. The compilation is an exhaustive effort on fifty herbs or their ingredients used globally and known to possess antifibrotic properties.
2. Methodology
Relevant published reports on liver fibrosis were collected since 1998 to 2015 by direct search on popular search engines for scientific literature retrieval, such as Elsevier-Science direct, Google Scholar, PubMed and Science Research. It is during the last 20 years that liver fibrosis has gained importance as a reversible stage of liver damage. The following key words phytoremediation, phytomedicine, plant, plant extracts, herbs, botanicals, alternative medicine were cross-referenced with the key words: liver fibrosis, liver cirrhosis, anti-fibrotic activity, experimental model of hepatic/liver fibrosis. The report clusters were searched for the details on model organisms used in the experiment for testing the activity of phytoproducts along with their mechanism of action.
3. Molecular mechanism of liver fibrosis
Hepatic fibrosis activation comprises two primary major steps: i) initiation and ii) perpetuation. Initiation is linked with paracrine mediated changes in gene expressions as cells become receptive to cytokines and other stimuli. Perpetuation is the result of maintenance of these signals which lead to further increase in cytokine secretion and progression of extracellular matrix remodeling.
Several cytokines and growth factors are crucial in the initiation of hepatic fibrogenesis. Transforming growth factor β (TGF-β) is the main fibrogenic cytokine released by kupffer cells, endothelial cells and hepatocytes in the liver and is a key mediator in human fibrogenesis.18 It has three major isoforms: TGF-β1, TGF-β2 and TGF-β3. TGF-β1 is stored as an inactivated protein and when activated, signals through its receptors to Smad proteins, which increase the transcription of target genes such as procollagen I and III.19 It has a role in transition of HSCs to myofibroblast like cells, triggers the synthesis of ECM proteins and retards their degradation. Platelet derived growth factor (PDGF) is potent mitogen for HSCs and is upregulated in liver fibrosis and; its inhibition alleviates hepatic fibrosis in experimental animals.20 Endothelin-1, a powerful vasoconstrictor, stimulates fibrogenesis by its type A receptor.21 Angiotensin-II, a vasoactive cytokine, also plays a key role in liver fibrogenesis. It induces liver inflammation and triggers a series of fibrogenic activity in activated HSCs, including secretion of proinflammatory cytokines, cell proliferation, cell migration and synthesis of collagen.22 Adipokines are cytokines mainly secreted in adipose tissue and to a lesser extent by stromal cells. Leptin, adiponectin and ghrelin are main adipokines that contribute to liver injury.23, 24 Leptin is required for activation of HSCs and fibrosis development.25 In contrast, adiponectin markedly inhibits hepatic fibrosis both in vitro and in vivo.24 Ghrelin also attenuates liver fibrosis in experimental animals.26 Peroxisome proliferator activated receptors (PPARs) regulate lipid and glucose metabolism and their expression decreases with the activation of HSCs.27, 28 In contrast, PPAR-γ impedes the fibrogenic actions in HSCs and attenuates hepatic fibrosis.29, 30 Toll-like receptors (TLR) are highly conserved family of receptors that help in recognition of pathogen-associated molecular patterns and assist the host cells to identify microbial infection. It has been reported that activation of TLR-4 by lipopolysaccharide upregulates chemokine secretion and sensitizes HSCs so that TGF-β can act upon.31 TLR-4 signalling also induces the expression of fibrogenic cytokines such as TNF-α, IL-1 and IL-2.
There are also several markers which indicate the progression of hepatic fibrosis. Alpha-smooth muscle actin (α-SMA) is a reliable marker of HSCs activation which precedes fibrous tissue deposition and is used for identification of earlier stages of liver fibrosis.5, 7 Cyclooxygenases (COX) are key enzymes in the metabolism of arachidonic acid to produce prostaglandins (PGs) which are involved in the formation of tumors. It exists in two isoforms, COX-1 and COX-2. While COX-1 is expressed in wide variety of tissues, COX-2 is induced by various cytokines, growth factors, and mitogens.32 It has a major role in inflammation and carcinogenesis and is related with various liver diseases.33 It is reported that quiescent HSCs do not express COX-2 but activated HSCs in culture express COX-2, which indicates its involvement in hepatic fibrogenesis.34
4. Active ingredients of plants for treatment of liver fibrosis
So far, there is no specific and effective antifibrotic therapy on record, though possible candidates might include endothelin receptor antagonists, rennin angiotensin inhibitors, PPAR-γ agonists and TGF-β signaling inhibitors. Besides, varieties of complications are caused by synthetic drugs. Therefore, further research should focus on herbal medicine that are claimed to possess anti-hepatic fibrotic properties. Families of fabaceae, asteraceae and lamiaceae cover the largest number of anti-fibrotic plants. These plants usually contain phytochemicals such as flavonoids, alkaloids, phenols, quinones, glycosides etc. The active ingredients of each plant which fall in the category of these phytochemicals, play a key role in the treatment of hepatic fibrosis. Among many such active ingredients, silymarin, armepavine, plumbagin, rhein, glycyrrhetinic acid, ginseng, epigallocatechin-3-gallate, curcumin, salvianolic acid and osthole have been extensively studied and documented.
4.1. Silymarin
Silymarin is a flavonoid complex consisting of silybin, silydianin and silychrisin and is extracted from the seeds of Silybum marianum. Silymarin is a strong antioxidant that promotes liver cell regeneration, reduces blood cholesterol, and helps in preventing cancer.35 It assists in combating hepatic fibrosis by restoring the level of α-SMA in CCl4 treated rats.36 α-SMA is a well known marker of hepatic stellate cells activation leading to fibrous tissue deposition37 and also a reliable marker of myofibroblast like cell recognition in both rat and man.38 It is reported that decrease in α-SMA level is accompanied by reduction in the number of activated HSCs.39 Therefore, silymarin assists in promoting apoptosis of activated HSCs. It is reported that treatment with silymarin and its constituents are safe with no adverse effects.40
4.2. Armepavine
Armepavine is an active alkaloid compound derived from plant Nelumbo nucifera. It exerts anti-inflammatory effects on human peripheral blood mononuclear cells and immunosuppressive effects on lupus nephritic mice and on T lymphocytes.41, 42 It can attenuate liver fibrosis by down-regulating the expression of TNF-α stimulated α-SMA expression in thioacetamide induced rats.43 TNF-α, a cytokine involved in inflammation, can also down-regulate metallothionein mRNA expression in thioacetamide induced rats. Metallothionein is reported to control intracellular redox level and regulate NF-κβ and other redox-regulated transcription factors,44 thus, reducing fibrosis. Possibly, through anti-NF-κβ activation pathways, armepavine exerts both in-vitro and in-vivo anti-fibrotic effects in rats.45
4.3. Plumbagin
Plumbagin is an active napthoquinone extracted from the roots of traditional medicinal plant Plumbago zeylanica L. It possesses several pharmacological properties, such as the induction of apoptosis, anti-inflammation, anti-angiogenesis, antioxidant activity and anti-cancer.46, 47, 48 Plumbagin increases the matrix metalloproteinase-1 (MMP-1) expression which is beneficial for ECM degradation.49 It decreases the content of type-I collagen and HSC activation and thus, restoring the normal functions of HSCs.49 It reduces the activation of HSCs by targeting EGFR signalling pathway which may prove a potential therapeutic strategy to treat hepatic fibrosis.50 There is a prominent inflammation associated correlation between TNF-α and α-SMA and, plumbagin reportedly decreases the expression of these two in CCl4 lesioned rats thus, contributing to degradation of ECM for mitigating liver fibrosis.51
4.4. Rhein
Rhein, an anthraquinone, is one of the most important active components of rhubarb (Rheum officinale), a traditional Chinese herb to treat chronic liver disease. It possesses several biological properties such as anti-microbial, anti-angiogenic and anti-cancer activities.52, 53, 54, 55 In CCl4 induced rats, Rhein inhibits TGF-β1 which plays a central role in liver inflammation.56 It also inhibits α-SMA, preventing the activation of hepatic stellate cells and thus reducing hepatic fibrosis.56
4.5. Glycyrrhetinic acid
Glycyrrhetinic acid (GA) is one of the derivative products of Glycyrrhizic acid. It is the most effective medicine available in clinics and is extracted from Glycirrhiza glabra. It has several pharmacological properties like, antiviral, anti-mutagenic, anti-inflammatory, anti-injury and antioxidant properties as well as liver protection.57, 58, 59, 60, 61, 62 It protects liver from reactive hydroxyl radicals derived from H2O2 by upregulating Nrf-2, raising its target gene catalase expression in CCl4 induced liver fibrosis in rats.63 Expression of type I and type III collagen are also down-regulated by GA,64 thereby preventing hepatic fibrosis.
4.6. Ginseng
Ginseng, referred to as the roots of Panax ginseng, possesses biological properties that include anti-cancer, anti-inflammatory and anti-diabetic, as well as cardiovascular- and neuro-protection.65, 66, 67 COX-2 expression is stimulated by TNF-α and IL-1β during CCl4 induced liver fibrosis in rats while ginseng suppresses TNF-α and IL-1β mRNA expression,68 thus, preventing inflammation. It mitigates fibrosis by reducing α-SMA expression69 and inhibition of the HSCs activation and thus helps to stop fibrogenesis.
4.7. Epigallocatechin-3-gallate
Epigallocatechin-3-gallate (EGCG) is the most abundant and active polyphenol in green tea (Camellia sinensis). It is a powerful antioxidant that has attracted considerable attention because of its role in preventing oxidative stress-related diseases including cancers, cardiovascular diseases and fibrosis.70, 71, 72 MMP-2 increased expression and activity is one of the major causes of hepatic fibrosis. Increase in the MMP-2 activity is related with an enhanced destruction of normal liver architecture, stimulating its replacement by interstitial collagen.73 EGCG suppresses the expression of endogenous MMP-2 mRNA and subsequent protein expression.74 It has been reported that in CCl4 induced liver fibrosis, EGCG suppresses MMP-2 activity via down-regulating NF-κβ expression.74 It also decreases COX-2 and iNOS expression through regulation of the activities of NF-κβ and C/EBP-α respectively.75
4.8. Curcumin
Curcumin is a polyphenol and the main active compound found in the plant Curcuma longa (commonly known as turmeric). It has various biological activities such as anticancer, antiviral, antioxidant and anti-inflammatory activities.76, 77, 78, 79 It affects cell proliferation by inhibiting the expression of NF-κβ in CCl4 induced liver fibrosis and also triggers apoptosis by activating caspase-3 and caspase-9, and by changing nuclear morphology and phosphotidylserine expression.80, 81 TGF-β1 signals transmembrane receptors stimulating cytoplasmic proteins i.e., Smad proteins which, in turn, modulate the transcription of target genes including those of ECM components, procollagen-I and -III.82 Curcumin inhibits hepatic TGF-β1 expression in liver tissues83 and thus it prevents the deposition of ECM in fibrosis.
4.9. Salvianolic acid
Salvianolic acid (SA) is a phenolic compound extracted from Salvia miltiorrhiza. It has been reported to exert free radical scavenging and anti-peroxidative effects in liver microsomes, hepatocytes and erythrocytes.84 SA suppresses the expression of TGF-β1 and α-SMA in CCl4 induced liver fibrosis in rats85 and inhibits inflammation and fibrogenesis. TNF-α and IL-1β are recognized as pro-inflammatory cytokines in various liver diseases, and SA reduces their expression,86 thus prevents inflammation and declines liver fibrosis.
4.10. Osthole
Osthole is a coumarin compound present in many medicinal plants especially in the fruit of Cnidium monnieri L. Cusson. It possesses various pharmacological properties, such as anti-oxidation and anti-inflammation.87 It is reported to reduce α-SMA in thioacetamide-induced liver fibrosis in rats88; which suppresses HSC activation. It also inhibited both TNF-α induced NF-κβ and TGF-β induced α-SMA activity in HSCs,88 consequently leading to inhibition of fibrogenesis.
5. Current phyto-products in treating liver fibrosis
Table 1 displays the names of the herbs/botanicals together with the extract used or the compound isolated from a particular herb. The table also demonstrates the suggested molecular mechanisms of amelioration of a particular herb/drug on hepatic fibrosis in test animals.
Table 1.
Herbs along with their active ingredients demonstrating molecular mechanism against hepatic fibrosis.
S. No. | Plant | Family | Part/Extract/Active ingredient | Experimental model | Type of study | Biomarkers/parameters affected | Reference |
---|---|---|---|---|---|---|---|
1 | Black bean | Fabaceae | Methanolic extract | CCl4 induced | In vivo | ↓liver types I and IV collagen | 89 |
2 | Pureria lobata | Fabaceae | Purerin | Alchol + CCl4 induced | In vivo | ↓serum AST, ALT, bcl-2 mRNA expression; ↑apoptosis of HSCs | 90 |
3 | Astragalus complanatus | Fabaceae | Flavonoids | NDMA induced | In vivo | ↑SOD, MMP-1 mRNA, ↓MDA, serum PINP and PIIINP and TIMP-1 | 91 |
4 | Astragalus membranaceous | Fabaceae | Root extract | CCl4 induced | In vivo | ↓serum transaminases, hyaluronic acid, laminin and procollagen type III levels, and contents of hydroxyproline, LPO and TGF-β; ↑SOD and GSH-Px; ↓thymidine and proline incorporation. | 92 |
5 | Glycyrrhiza glabra | Fabaceae | Glycyrrhetinic Acid | CCl4 induced | In vivo | ↓ALT, AST, MAO, LPO; ↑Nrf2, SOD 3, GPX2 and CAT | 63 |
6 | Cichorium glandulosum | Compositae/ Asteraceae |
Root extract (petroleum ether, ethyl acetate, and n-butyl alcohol) | CCl4 induced | In vivo | ↓serum AST, ALT, FN, Smard3 and TGF-β1; ↑apoptotic index | 93 |
7 | Silybum marianum | Asteraceae | Silymarin | CCl4 induced | In vivo | ↓serum AST, ALT, ALP hepatic α-SMA | 36 |
8 | Artemisia iwayomogi | Asteraceae | Plant extract (ethanol, methanol and hot water) | CCl4 induced | In vivo | ↓ liver hydroxyproline, α-SMA, MDA and serum cholesterol | 94 |
9 | Bidens pilosa | Asteraceae | Total flavonoids | CCl4 induced | In vivo | ↓serum ALT, AST levels, hepatic MDA and NF-κB; ↑SOD and GSH-Px | 95 |
10 | Vitex negundo | Lamiaceae | Ethanolic extract | Thioacetamide induced | In vivo | ↓serum AST, ALT, ALP and bilirubin; ↑serum albumin; ↓triglyceride, LDL and total cholestrol | 96 |
11 | Salvia miltiorrhiza | Lamiaceae | Salvionolic acid | CCl4 induced | In vivo | ↓TGF-β1, procollagens I and III and tissue inhibitor of metalloproteinase-1 transcripts; ↑ matrix metalloproteinase-13 | 97 |
12 |
Scutellaria baicalensis |
Lamiaceae | Methanolic root extract | bile duct ligation or carbon tetrachloride induced | In vivo | ↓MDA, hydroxyproline, α-SMA and serum enzymes (AST, ALT, ALP and total bilirubin) | 98 |
13 | Amomum xanthoides | Zingiberaceae | Methanolic fraction | Thioacetamide induced | In vivo | ↓serum bilirubin, liver hydroxyproline and MDA, GSH, GPx, iNOS, TNF-α, TGF-β, PDGF-β, CTGF | 99 |
14 | Zingiber officinale | Zingiberaceae | Rhizome extract (petroleum, ether, chloroform, ethanol) | CCl4 induced | In vivo | ↑GSH, SOD, SDH, LDH, G-6-Pase, AP and 5′ NT; ↓ MDA, AST, ALT ALP, GGT and total bilirubin | 100 |
15 | Turmeric | Zingiberaceae | Curcumin | CCl4 induced | In vivo | ↓α-SMA; ↑apoptotic index | 101 |
16 | Panax ginseng | Araliaceae | Ginseng | CCl4 induced | In vivo | ↓serum ALT, AST, α-SMA and expression of m RNAs of TGF-β and PAI-1 | 102 |
17 | Panax notoginseng | Arialiaceae | Root water extract | Hepatic microvascular dysfunction | In vivo | ↓sera transaminases and bilirubin | 103 |
18 | Cnidium monnieri | Apiaceae | Osthole | Thioacetamide induced | In vivo and in vitro | ↓serum AST, ALT, hepatic collagen, α-SMA, TGF-β1 and NF-κB activities | 88 |
19 | Bupleurum kaoi | Apiaceae | Root extract | NDMA induced | In vivo | ↓serum ALT, AST, collagen of liver; ↑total protein, albumin of liver and serum, IFN-γ and IL-10 of serum and hepatic GSH | 104 |
20 | Ginkgo biloba | Ginkgoaceae | Green leaves extract | CCl4 induced | In vivo | ↓serum AST, ALT and bilirubin; ↑serum albumin; ↓liver collagen, reticulin, TIMP-1 and α-SMA; ↑MMP-1 | 105 |
21 | Camellia sinensis | Theaceae | Epigallocatechin-3-gallate | CCl4 induced | In vivo and in vitro | ↓serum ALT, AST, histological and hepatic hydroxyproline, α-SMA and MMP-2 | 74 |
22 | Solanum nigrum | Solanaceae | Whole plant extract | Thioacetamide induced | In vivo | ↓hepatic hydroxyproline, α-SMA, collagen (α1) (I), TGF-β1 | 106 |
23 | Stephania tetrandra | Menispermaceae | Tetrandrine | NDMA induced | In vivo and in vitro | ↓ NFκB, ICAM-1, α-SMA, and TGF-β1, hepatic collagen deposition and serum AST, ALT | 107 |
24 | Cudrania cochinchinensis | Moraceae | Water extract | CCl4 induced | In vivo | ↓serum AST, ALT, procollagen-III, hyluronic acid and liver hydroxyproline; ↑serum total protein, albumin and SOD | 108 |
25 | Blue berry | Ericaceae | Fresh fruit juice | CCl4 induced | In vivo | ↓α-SMA, collagen-III and MDA; ↑metallothionein and SOD | 109 |
26 | Turnip | Brassicaceae | Water extract | Thioacetamide induced | In vivo | ↓serum AST, ALT | 110 |
27 | Ganoderma lucidum | Ganodermataceae | Crude extract | CCl4 induced | In vivo | ↑plasma albumin, A/G ratio; ↓serum AST, ALT, TGF-β1, hepatic hydroxyproline, MDA and changes in expression of MAT 1A and MAT 2A. | 111 |
28 | Phellinus linteus | Hymenochaetaceae | Polysaccharide extract | Thioacetamide induced | In vivo | 13 proteins showing differential expression are actin, tubulin alpha-1C chain, preprohaptoglobin, hemopexin, galectin-5, glutathione S-transferase alpha-4 (GSTA4), branched chain keto acid dehydrogenase heterotetrameric E1 subunit alpha (BCKDHA), glutathione S-transferase mu (GSTmu), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), thiosulfate sulfurtransferase (TFT), betaine-homocysteine S-methyltransferase 1 (BHMT1), quinoid dihydropteridine reductase (QDPR), ribonuclease UK114 | 112 |
29 | Allium sativum | Amaryllidaceae | Peeled garlic extract | CCl4 induced | In vivo | ↓serum AST, ALT, α-SMA, IL-1, tissue transglutaminase mRNA and tissue transglutaminase protein |
113 |
30 | Lygodium flexuosum | Lygodiaceae | Whole plant extract | CCl4 induced | In vivo | ↓serum AST, ALT, LDH, liver hydroxyproline | 114 |
31 | Dioscorea panthaica | Dioscoreaceae | Aqueous extract | CCl4 induced | In vivo | ↓hepatic hydroxyproline, LPO and α-SMA; ↑glutathione | 115 |
32 | Nelumbo nucifera | Nelumbonacea | Armepavine | TNF-α or lipopolysaccharide and bile duct ligation | In vivo and in vitro | ↓serum AST, ALT, hepatic α-SMA and collagen, AP-1; ↑metallothionein genes; ↓col 1α2, TGF-β1, TIMP-1, ICAM-1, iNOS, and IL-6 gene expression | 45 |
33 | Rhus javanica | Anacardeacea | Ethanol extract | Activated HSCs | In vitro | ↓ Col 1 α2, TGF-β, α-SMA | 116 |
34 | Litsea coreana | Lauraceae | Total flavonoids | CCl4 induced | In vivo | ↓AST, ALT hyaluronic acid, laminin, procollagen III N-terminal peptide, procollagenase IV, hydroxyproline, α-SMA, TGF-β1, TGFβR1, |
117 |
35 | Apricot | Rosaceae | Kernel | NDMA induced | In vivo | ↓serum AST, ALT and MDA; ↓SOD, CAT and GSH | 118 |
36 | Punica granatum | Punicaceae | Peel | Biliary obstructed | In vivo | ↓serum AST, ALT, LDH and cytokines; ↑plasma AOC and GSH; ↓ hepatic MDA and MPO level | 119 |
37 | Plumbago zeylanica | Plumbaginaceae | Plumbagin | CCl4 induced | In vivo and in vitro | ↓serum AST, ALT, α-SMA, EGFR, STAT3 and HB-EGF | 50 |
38 | Rheum officinale | Polygonaceae | Rhein | CCl4 induced | In vivo | ↓ALT, hyaluronic acid, procollagen, MDA, α-SMA and TGF-β1 | 56 |
39 | Operculina turpethum | Convolvulaceae | Root extract | NDMA induced | In vivo | ↓micronuclei count, liver function enzymes, serum hydroxyproline, LDH isoenzymes 4 and 5 and α-SMA | 7 |
40 | Hibiscus sabdariffa | Malvaceae | Dried flower extract | CCl4 induced | In vivo and in vitro | ↓AST, ALT, LPO and activated hepatic stellate cells; ↑glutathione | 120 |
41 | Paeonia lactiflora | Paeoniaceae | Root extract | CCl4 induced | In vivo | ↓serum transaminases, hyaluronic acid, laminin and procollagen type III levels, and contents of hydroxyproline, LPO and TGF-β; ↑SOD and GSH-Px; ↓thymidine and proline incorporation | 92 |
42 | Moringa oleifera | Moringaceae | Seed extact | CCl4 induced | In vivo | ↓serum aminotransferase activities, globulin, hydroxyproline, myeloperoxidase, collagens I and III, α-SMA, protein carbonyl and MDA; ↑SOD and antioxidant properties | 121 |
43 | Nigella sativa | Ranunculaceae | Oil extract | CCl4 induced | In vivo | ↓α-SMA and lysozyme | 122 |
44 | Urtica dioica | Urticaceae | Oil and decoction extract | CCl4 induced | In vivo | ↓α-SMA and lysozyme | 122 |
45 | Grape | Vitaceae | Resveratrol | NDMA induced | In vivo | ↓sera transaminases, ALP, bilirubin, LPO, protein carbonyl, hydroxyproline and α-SMA; ↑liver glycogen, SOD, ATPases (Ca2+, Mg2+, Na+/K+) |
5 |
46 | Zizyphus spina-christi | Rhamnaceae | Water extract | CCl4 induced | In vivo | ↓ALT, AST, LPO, collagen type I and III; ↑SOD, CAT and GSH | 123 |
47 | Fraxinus rhynchophylla | Oleaceae | Ethanol extract | CCl4 induced | In vivo | ↓ALT, AST and protein levels of uPA, MMP-2, MMP-9 and TIMP-1; ↑catalase, SOD and GPx | 124 |
48 | Dunalliela salina | Dunaliellaceae | β-Carotene | CCl4 induced | In vivo | ↓ALT, AST,ALP, LPO; ↑SOD, catalase, GSH-Px, glutathione reductase, and GSH | 125 |
49 | Cordyceps sinensis | Cordycipitaceae | Whole extract | NDMA induced | In vivo | ↓hydroxyproline,TIMP-2, collagen type I and IV | 126 |
50 | Aloe vera and Silybum marianum | Xanthorrhoeaceae and Asteraceae | ACTIValoe®N-931 complex | CCl4 induced | In vivo | ↓serum ALT, AST, hepatic MDA hydroxyproline, TGF-β1, TIMP-1 and expression of TNF-α, iNOS, COX-2 mRNA; ↑hepatic glutathione | 127 |
List of abbreviations given in the Table: ↑ = Increase; ↓ = Decrease; ALP = Alkaline phosphatase; ALT = Alanine transaminase; AST = Aspartate transaminase; CCl4 = Carbon tetrachloride; COX-2 = Cycloxygenase 2; CTGF = Connective tissue growth factor; FN = Fibronectin; GPx = Glutathione peroxidase; GSH = Glutathione; ICAM-1 = Intercellular adhesion molecule 1; IL-1 = Interleukin 1; iNOS = Inducible nitric oxide synthase; MAT 1A = Methionine adenosyltransferase 1 alpha; MDA = Malondialdehyde; MMP-1 = Matrix metalloproteinase 1; NFκB = nuclear factor kappa-light-chain-enhancer of activated B cells; PAI-1 = Plasminogen activator inhibitor 1; PDGF-β = Platelet derived growth factor beta; PINP = Type 1 procollagen peptide; SOD = Superoxide dismutase; TGF-β = Transforming growth factor beta; TIMP-1 = Tissue inhibitor of metalloproteinase 1; TNF-α = Tumor necrosis factor alpha; α-SMA = Alpha smooth muscle actin; uPA = Urokinase.
6. Conclusions
In conclusion, this review amply demonstrates that the herbal products can protect the liver from oxidative stress, inflammation and ceases fibrogenesis (Fig. 4). It is expected that integrated tabulation of herbs with corresponding medicinal properties will facilitate identification of different ingredients with similar bioactivities or similar ingredients with different bioactivities. As the drug discovery is becoming increasingly extortionate, unsafe and ineffective, plant products offer better alternatives, since they have traditionally served as modest means of disease containment. About half of the drugs in use today are procured from plant products. However, the evidence supporting the use of herbal products for treating liver fibrosis is inadequate and only few of them are well standardized and also free of serious side effects. Therefore, successful development of novel and promising therapies for liver fibrosis requires careful designs using various experimental approaches. The standardization and characterization of natural products should be complimentary to success with animal models. The key cytokines regulating the process of fibrosis, the markers of ongoing fibrosis and advances in the molecular research techniques also have highlighted a number of potential therapeutic approaches that are suitable for future development for treating this disease. Because of logistic and legal problems such as restrictions to liver biopsies, the efficacy of antifibrotic treatments to attenuate experimental liver fibrosis has not been documented in humans, so far. Consequently, the ideal antifibrotic agent which is liver specific, safe when used for prolonged periods of time and inexpensive has yet to be discovered. Certain herbal formulations are in clinical trials, but their effectiveness as antifibrotic medicine is not proven. Silybin-phospholipids and vitamin E complex (SPV complex) treatment significantly reduces liver fibrosis and down-regulated fibrosis markers in fatty liver associated HCV patients.128 Chinese medicine Fuzhenghuayu (FZHY), having active ingredients salvianoic acid B and adenosine, also helps to prevent hepatic fibrosis and improves liver functions in humans.129, 130 It should be expected that the laboratory success of clinical trials with botanical pharmaceuticals would pave the way to successfully treat human fibrosis.
Fig. 4.
Schematic representation of active ingredients of phyto-medicine used in the treatment of liver fibrosis.
Declaration of interest
The authors declare no potential conflict of interest and are responsible for the writing and content of the paper.
Acknowledgement
The authors sincerely thank the Chairman, Department of Zoology for necessary facilities. UL acknowledges the financial assistance from Non-NET UGC Fellowship. The authors are grateful to Dr. Absar-ul Hasnain for critical reading and suggestions on the Manuscript.
Footnotes
Peer review under responsibility of The Center for Food and Biomolecules, National Taiwan University.
References
- 1.Shahani S. Evaluation of hepatoprotective efficacy of APLC: a herbal formulation in vivo in rats. Ind Drugs. 1999;36:628–631. [Google Scholar]
- 2.Subramoniam A., Pushpangadan P. Development of phytomedicines for liver disease. Ind J Pharmacol. 1999;31:166. [Google Scholar]
- 3.Mustafa M.E., Mansoor M.M., Mohammed A., Babker A.A.A. Evaluation of platelets count and coagulation parameters among patients with liver disease. World J Pharm Res. 2015;368:360–368. [Google Scholar]
- 4.Zhang A., Sun H., Wang X. Recent advances in natural products from plants for treatment of liver diseases. Eur J Med Chem. 2013;63:570–577. doi: 10.1016/j.ejmech.2012.12.062. [DOI] [PubMed] [Google Scholar]
- 5.Ahmad A., Ahmad R. Resveratrol mitigate structural changes and hepatic stellate cell activation in N′-nitrosodimethylamine-induced liver fibrosis via restraining oxidative damage. Chem Biol Interac. 2014;221:1–12. doi: 10.1016/j.cbi.2014.07.007. [DOI] [PubMed] [Google Scholar]
- 6.Ahmad A., Ahmad R. Understanding the mechanism of hepatic fibrosis and potential therapeutic approaches. Saudi J Gastroenterol. 2012;18:155–167. doi: 10.4103/1319-3767.96445. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Ahmad R., Ahmed S., Khan N.U., Hasnain A.U. Operculina turpethum attenuates N-nitrosodimethylamine induced toxic liver injury and clastogenicity in rats. Chem Biol Interac. 2009;181:145–153. doi: 10.1016/j.cbi.2009.06.021. [DOI] [PubMed] [Google Scholar]
- 8.Friedman S.L. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem. 2000;275:2247–2250. doi: 10.1074/jbc.275.4.2247. [DOI] [PubMed] [Google Scholar]
- 9.Forbes S.J., Russo F.P., Rey V. A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. Gastroenterology. 2004;126:955–963. doi: 10.1053/j.gastro.2004.02.025. [DOI] [PubMed] [Google Scholar]
- 10.Naghavi M., Wang H., Lozano R. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the global burden of disease study 2013. Lancet. 2015;385:117–171. doi: 10.1016/S0140-6736(14)61682-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Jemal A., Murray T., Ward E. Cancer statistics, 2005. CA: Can J Clin. 2005;55:10–30. doi: 10.3322/canjclin.55.1.10. [DOI] [PubMed] [Google Scholar]
- 12.Leong T.Y.M., Leong A.S.Y. Epidemiology and carcinogenesis of hepatocellular carcinoma. HPB. 2005;7:5–15. doi: 10.1080/13651820410024021. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Astin J.A. Why patients use alternative medicine: results of a national study. J Am Med Assoc. 1998;279:1548–1553. doi: 10.1001/jama.279.19.1548. [DOI] [PubMed] [Google Scholar]
- 14.World Health Organization . WHO Regional Office for the Western Pacific; Manila: 1993. Research Guidelines for Evaluating the Safety and Efficacy of Herbal Medicines. [Google Scholar]
- 15.Mirghafourvand M., Mohammad-Alizadeh-Charandabi S., Ahmadpour P., Javadzadeh Y. Effects of Vitex agnus and Flaxseed on cyclic mastalgia: a randomized controlled trial. Complem Ther Med. 2016;24:90–95. doi: 10.1016/j.ctim.2015.12.009. [DOI] [PubMed] [Google Scholar]
- 16.Rai M.K. Herbal medicines in India: retrospect and prospect. Fitoterapia. 1994;65:483–491. [Google Scholar]
- 17.MacIntosh A.M. Understanding the differences between conventional, alternative, complementary, integrative and natural medicine. Towns Lett July. 1999 tldp.com/medicine.htm [Google Scholar]
- 18.Inagaki Y., Okazaki I. Emerging insights into transforming growth factor β Smad signal in hepatic fibrogenesis. Gut. 2007;56:284–292. doi: 10.1136/gut.2005.088690. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Yoshida K., Matsuzaki K. Differential regulation of TGF-β/Smad signaling in hepatic stellate cells between acute and chronic liver injuries. Front Physiol. 2012 Mar;3:53. doi: 10.3389/fphys.2012.00053. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Pinzani M., Gesualdo L., Sabbah G.M., Abboud H.E. Effects of platelet-derived growth factor and other polypeptide mitogens on DNA synthesis and growth of cultured rat liver fat-storing cells. J Clin Invest. 1989;84:1786–1793. doi: 10.1172/JCI114363. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Cho J.J., Hocher B., Herbst H. An oral endothelin-A receptor antagonist blocks collagen synthesis and deposition in advanced rat liver fibrosis. Gastroenterology. 2000;118:1169–1178. doi: 10.1016/s0016-5085(00)70370-2. [DOI] [PubMed] [Google Scholar]
- 22.Bataller R., Gäbele E., Schoonhoven R. Prolonged infusion of angiotensin II into normal rats induces stellate cell activation and proinflammatory events in liver. Am J Physiol Gastrointest Liver Physiol. 2003;285:G642–G651. doi: 10.1152/ajpgi.00037.2003. [DOI] [PubMed] [Google Scholar]
- 23.Marra F., Bertolani C. Adipokines in liver diseases. Hepatology. 2009;50:957–969. doi: 10.1002/hep.23046. [DOI] [PubMed] [Google Scholar]
- 24.Korah T.E., El-Sayed S., ElShafie M.K., Hammoda G.E., Safan M.A. Significance of serum leptin and adiponectin levels in Egyptian patients with chronic hepatitis C virus associated hepatic steatosis and fibrosis. World J Hepatol. 2013;5:74–81. doi: 10.4254/wjh.v5.i2.74. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Ikejima K., Takei Y., Honda H. Leptin receptor–mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology. 2002;122:1399–1410. doi: 10.1053/gast.2002.32995. [DOI] [PubMed] [Google Scholar]
- 26.Moreno M., Chaves J.F., Sancho-Bru P. Ghrelin attenuates hepatocellular injury and liver fibrogenesis in rodents and influences fibrosis progression in humans. Hepatology. 2010;51:974–985. doi: 10.1002/hep.23421. [DOI] [PubMed] [Google Scholar]
- 27.Zhang F., Kong D., Lu Y., Zheng S. Peroxisome proliferator-activated receptor-γ as a therapeutic target for hepatic fibrosis: from bench to bedside. Cell Mol Life Sci. 2013;70:259–276. doi: 10.1007/s00018-012-1046-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Lee U.E., Friedman S.L. Mechanisms of hepatic fibrogenesis. Best Prac Resh Clin Gastroenterol. 2011;25:195–206. doi: 10.1016/j.bpg.2011.02.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Marra F., Efsen E., Romanelli R.G. Ligands of peroxisome proliferator-activated receptor-γ modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology. 2000;119:466–478. doi: 10.1053/gast.2000.9365. [DOI] [PubMed] [Google Scholar]
- 30.Galli A., Crabb D.W., Ceni E. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology. 2002;122:1924–1940. doi: 10.1053/gast.2002.33666. [DOI] [PubMed] [Google Scholar]
- 31.Seki E., De Minicis S., Österreicher C.H. TLR-4 enhances TGF-β signaling and hepatic fibrosis. Nat Med. 2007;13:1324–1332. doi: 10.1038/nm1663. [DOI] [PubMed] [Google Scholar]
- 32.Paik Y.H., Kim J.K., Lee J.I. Celecoxib induces hepatic stellate cell apoptosis through inhibition of Akt activation and suppresses hepatic fibrosis in rats. Gut. 2009;58:1517–1527. doi: 10.1136/gut.2008.157420. [DOI] [PubMed] [Google Scholar]
- 33.Hu K.Q. Cyclooxygenase-2 (COX2)-prostanoid pathway and liver diseases. PLEFA. 2003;69:329–337. doi: 10.1016/j.plefa.2003.07.001. [DOI] [PubMed] [Google Scholar]
- 34.Efsen E., Bonacchi A., Pastacaldi S. Agonist-specific regulation of monocyte chemoattractant protein-1 expression by cyclooxygenase metabolites in hepatic stellate cells. Hepatology. 2001;33:713–721. doi: 10.1053/jhep.2001.22761. [DOI] [PubMed] [Google Scholar]
- 35.Vaknin Y., Hadas R., Schafferman D., Murkhovsky L., Bashan N. The potential of milk thistle (Silybum marianum L.), an Israeli native, as a source of edible sprouts rich in antioxidants. Int J Food Sci Nutr. 2007;20:1–8. doi: 10.1080/09637480701554095. [DOI] [PubMed] [Google Scholar]
- 36.Tsai J.H., Liu J.Y., Wu T.T. Effects of silymarin on the resolution of liver fibrosis induced by carbon tetrachloride in rats. J Vir Hep. 2008;15:508–514. doi: 10.1111/j.1365-2893.2008.00971.x. [DOI] [PubMed] [Google Scholar]
- 37.Carpino G., Morini S., Corradini S.G. Alpha-SMA expression in hepatic stellate cells and quantitative analysis of hepatic fibrosis in cirrhosis and in recurrent chronic hepatitis after liver transplantation. Dig Liv Dis. 2005;37:349–356. doi: 10.1016/j.dld.2004.11.009. [DOI] [PubMed] [Google Scholar]
- 38.Nouchi T., Tanaka Y., Tsukada T., Sato C., Marumo F. Appearance of α-smooth muscle actin positive cells in hepatic fibrosis. Liv Int. 1991;11:100–105. doi: 10.1111/j.1600-0676.1991.tb00499.x. [DOI] [PubMed] [Google Scholar]
- 39.Parsons C.J., Bradford B.U., Pan C.Q. Antifibrotic effects of a tissue inhibitor of metalloproteinase-1 antibody on established liver fibrosis in rats. Hepatology. 2004;40:1106–1115. doi: 10.1002/hep.20425. [DOI] [PubMed] [Google Scholar]
- 40.Morazzoni P., Bombardelli E. Silybum marianum (Carduus marianus) Fitoterapia. 1995;66:3–42. [Google Scholar]
- 41.Liu C.P., Tsai W.J., Lin Y.L., Liao J.F., Chen C.F., Kuo Y.C. The extracts from Nelumbo nucifera suppress cell cycle progression, cytokine genes expression, and cell proliferation in human peripheral blood mononuclear cells. Life Sci. 2004;75:699–716. doi: 10.1016/j.lfs.2004.01.019. [DOI] [PubMed] [Google Scholar]
- 42.Liu C.P., Tsai W.J., Shen C.C. Inhibition of (S)-armepavine from Nelumbo nucifera on autoimmune disease of MRL/MpJ-lpr/lpr mice. Eur J Pharmacol. 2006;531:270–279. doi: 10.1016/j.ejphar.2005.11.062. [DOI] [PubMed] [Google Scholar]
- 43.Weng T.C., Shen C.C., Chiu Y.T., Lin Y.L., Huang Y.T. Effects of armepavine against hepatic fibrosis induced by thioacetamide in rats. Phyt Res. 2012;26:344–353. doi: 10.1002/ptr.3539. [DOI] [PubMed] [Google Scholar]
- 44.Sakurai A., Hara S., Okano N., Kondo Y., Inoue J.I., Imura N. Regulatory role of metallothionein in NF-κB activation. FEBS Lett. 1999;455:55–58. doi: 10.1016/s0014-5793(99)00839-x. [DOI] [PubMed] [Google Scholar]
- 45.Weng T.C., Shen C.C., Chiu Y.T., Lin Y.L., Kuo C.D., Huang Y.T. Inhibitory effects of armepavine against hepatic fibrosis in rats. J Biomed Sci. 2009;16:78. doi: 10.1186/1423-0127-16-78. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Sinha S., Pal K., Elkhanany A. Plumbagin inhibits tumorigenesis and angiogenesis of ovarian cancer cells in vivo. Inter J Cancer. 2013;132:1201–1212. doi: 10.1002/ijc.27724. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Xu T.P., Shen H., Liu L.X., Shu Y.Q. Plumbagin from Plumbago Zeylanica L. induces apoptosis in human non-small cell lung cancer cell lines through NF-κB inactivation. Asia Pac J Cancer Preven. 2013;14:2325–2331. doi: 10.7314/apjcp.2013.14.4.2325. [DOI] [PubMed] [Google Scholar]
- 48.Checker R., Sharma D., Sandur S.K., Khanam S., Poduval T.B. Anti-inflammatory effects of plumbagin are mediated by inhibition of NF-κβ activation in lymphocytes. Int Immunopharmacol. 2009;9:949–958. doi: 10.1016/j.intimp.2009.03.022. [DOI] [PubMed] [Google Scholar]
- 49.Wei Y., Zhao T., Zhang Z. Plumbagin inhibits leptin-induced proliferation of hepatic stellate cells via JAK2-STAT3 pathway to protect against hepatic fibrosis. Trop J Pharm Res. 2013;12:691–698. [Google Scholar]
- 50.Chen S., Chen Y., Chen B. Plumbagin ameliorates CCl4-induced hepatic fibrosis in rats via the epidermal growth factor receptor signaling pathway. Evid-Bas Com Altern Med. 2015 doi: 10.1155/2015/645727. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Wei Y., Huang M., Liu X. Anti-fibrotic effect of plumbagin on CCl4-lesioned rats. Cell Physiol Biochem. 2015;35:1599–1608. doi: 10.1159/000373974. [DOI] [PubMed] [Google Scholar]
- 52.Wang J., Zhao H., Kong W. Microcalorimetric assay on the antimicrobial property of five hydroxyanthraquinone derivatives in rhubarb (Rheum palmatum L.) to Bifidobacterium adolescentis. Phytomedicine. 2010;17:684–689. doi: 10.1016/j.phymed.2009.10.009. [DOI] [PubMed] [Google Scholar]
- 53.He Z.H., Zhou R., He M.F. Anti-angiogenic effect and mechanism of rhein from rhizoma rhei. Phytomedicine. 2011;18:470–478. doi: 10.1016/j.phymed.2010.10.006. [DOI] [PubMed] [Google Scholar]
- 54.Chang C.Y., Chan H.L., Lin H.Y. Rhein induces apoptosis in human breast cancer cells. Evid-Based Comp Altern Med. 2012 doi: 10.1155/2012/952504. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Yang X., Sun G., Yang C., Wang B. Novel rhein analogues as potential anticancer agents. Chem Med Chem. 2011;6:2294–2301. doi: 10.1002/cmdc.201100384. [DOI] [PubMed] [Google Scholar]
- 56.Guo M.Z., Li X.S., Xu H.R., Mei Z.C., Shen W., Ye X.F. Rhein inhibits liver fibrosis induced by carbon tetrachloride in rats. Acta Pharmacol Sin. 2002;23:739–744. [PubMed] [Google Scholar]
- 57.Chen J., Pang J.L., Qin Y.M., Liang N.C. Effects of 18 β-glycyrrhetinic acid on the proliferation, adhesion and invasion in HO-8910PM cells. Shandong Med J. 2011;51:12–14. [Google Scholar]
- 58.Jin M., Wu H.J. Advancement on pharmacological action of glycyrrhetinic acid. Med Recapitul. 2009;15:1712–1715. [Google Scholar]
- 59.Gong X.L., Luo Y., Tang D.C., Sun X.F. Research progress in glycyrrhetic acid and its derivatives. Strait Pharmaceu J. 2008;20:4–7. [Google Scholar]
- 60.Luo Y., Zhu M.L., Sun X.F., Liang Z.Q. Preparation of water-soluble sodium salt of glycyrrhetinic acid and 11-deoxyglycyrrhetinic acid and research on anti-inflammatory effect. Prac Pharm Clin Remed. 2008;11:182–184. [Google Scholar]
- 61.Van Rossum T.G., De Man R.A. Glycyrrhizin as a potential treatment for chronic hepatitis C. Aliment Pharmacol Ther. 1998;12:199–205. doi: 10.1046/j.1365-2036.1998.00309.x. [DOI] [PubMed] [Google Scholar]
- 62.Kobashi K., Nanba T., Hattori Y. Preparation of 3-epi-glycyrrhetinic acid. JP. 1984:5914799. [Google Scholar]
- 63.Chen S., Zou L., Li L., Wu T. The protective effect of glycyrrhetinic acid on carbon tetrachloride-induced chronic liver fibrosis in mice via upregulation of Nrf 2. PLoS One. 2013;8:53662. doi: 10.1371/journal.pone.0053662. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Moro T., Shimoyama Y., Kushida M. Glycyrrhizin and its metabolite inhibit Smad3-mediated type I collagen gene transcription and suppress experimental murine liver fibrosis. Life Sci. 2008;83:531–539. doi: 10.1016/j.lfs.2008.07.023. [DOI] [PubMed] [Google Scholar]
- 65.Joo S.S., Won T.J., Lee D.I. Reciprocal activity of ginsenosides in the production of proinflammatory repertoire, and their potential roles in neuroprotection in vitro. Planta Med. 2005;71:476–481. doi: 10.1055/s-2005-864145. [DOI] [PubMed] [Google Scholar]
- 66.Jung C.H., Seog H.M., Choi I.W., Choi H.D., Cho H.Y. Effects of wild ginseng (Panax ginseng CA Meyer) leaves on lipid peroxidation levels and antioxidant enzyme activities in streptozotocin diabetic rats. J Ethnopharm. 2005;98:245–250. doi: 10.1016/j.jep.2004.12.030. [DOI] [PubMed] [Google Scholar]
- 67.Yun T.K., Choi S.Y., Yun H.Y. Epidemiological study on cancer prevention by ginseng: are all kinds of cancers preventable by ginseng? J Kor Med Sci. 2001;16:S19–S27. doi: 10.3346/jkms.2001.16.S.S19. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Hou Y.L., Tsai Y.H., Lin Y.H., Chao J.C. Ginseng extract and ginsenoside Rb1 attenuate carbon tetrachloride-induced liver fibrosis in rats. BMC Compl Altern Med. 2014;14:415. doi: 10.1186/1472-6882-14-415. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.Lu K.H., Weng C.Y., Chen W.C., Sheen L.Y. Ginseng essence, a medicinal and edible herbal formulation, ameliorates carbon tetrachloride-induced oxidative stress and liver injury in rats. J Gins Res. 2016:1–10. doi: 10.1016/j.jgr.2016.06.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70.Guo S., Lu J., Subramanian A., Sonenshein G.E. Microarray-assisted pathway analysis identifies mitogen-activated protein kinase signaling as a mediator of resistance to the green tea polyphenol epigallocatechin 3-gallate in her-2/neu–overexpressing breast cancer cells. Cancer Res. 2006;66:5322–5329. doi: 10.1158/0008-5472.CAN-05-4287. [DOI] [PubMed] [Google Scholar]
- 71.El Bedoui J., Oak M.H., Anglard P., Schini-Kerth V.B. Catechins prevent vascular smooth muscle cell invasion by inhibiting MT1-MMP activity and MMP-2 expression. Cardiovas Res. 2005;67:317–325. doi: 10.1016/j.cardiores.2005.03.017. [DOI] [PubMed] [Google Scholar]
- 72.Donà M., Dell'Aica I., Calabrese F. Neutrophil restraint by green tea: inhibition of inflammation, associated angiogenesis, and pulmonary fibrosis. J Immunol. 2003;170:4335–4341. doi: 10.4049/jimmunol.170.8.4335. [DOI] [PubMed] [Google Scholar]
- 73.Gaça M.D., Zhou X., Issa R., Kiriella K., Iredale J.P., Benyon R.C. Basement membrane-like matrix inhibits proliferation and collagen synthesis by activated rat hepatic stellate cells: evidence for matrix-dependent deactivation of stellate cells. Mat Biol. 2003;22:229–239. doi: 10.1016/s0945-053x(03)00017-9. [DOI] [PubMed] [Google Scholar]
- 74.Zhen M.C., Wang Q., Huang X.H. Green tea polyphenol epigallocatechin-3-gallate inhibits oxidative damage and preventive effects on carbon tetrachloride–induced hepatic fibrosis. J Nutri Biochem. 2007;18:795–805. doi: 10.1016/j.jnutbio.2006.12.016. [DOI] [PubMed] [Google Scholar]
- 75.Tipoe G.L., Leung T.M., Liong E.C., Lau T.Y., Fung M.L., Nanji A.A. Epigallocatechin-3-gallate (EGCG) reduces liver inflammation, oxidative stress and fibrosis in carbon tetrachloride (CCl4)-induced liver injury in mice. Toxicology. 2010;273:45–52. doi: 10.1016/j.tox.2010.04.014. [DOI] [PubMed] [Google Scholar]
- 76.Tu C.T., Han B., Liu H.C., Zhang S.C. Curcumin protects mice against concanavalin A-induced hepatitis by inhibiting intrahepatic intercellular adhesion molecule-1 (ICAM-1) and CXCL10 expression. Mol Cell Biochem. 2011;358:53–60. doi: 10.1007/s11010-011-0920-4. [DOI] [PubMed] [Google Scholar]
- 77.Aggarwal B.B., Harikumar K.B. Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases. Int. J Biochem Cell Biol. 2009;41:40–59. doi: 10.1016/j.biocel.2008.06.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 78.Rivera-Espinoza Y., Muriel P. Pharmacological actions of curcumin in liver diseases or damage. Liv Int. 2009;29:1457–1466. doi: 10.1111/j.1478-3231.2009.02086.x. [DOI] [PubMed] [Google Scholar]
- 79.Corson T.W., Crews C.M. Molecular understanding and modern application of traditional medicines: triumphs and trials. Cell. 2007;130:769–774. doi: 10.1016/j.cell.2007.08.021. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 80.Shu J.C., He Y.J., Lv X., Ye G.R., Wang L.X. Curcumin prevents liver fibrosis by inducing apoptosis and suppressing activation of hepatic stellate cells. J Nat Med. 2009;63:415–420. doi: 10.1007/s11418-009-0347-3. [DOI] [PubMed] [Google Scholar]
- 81.Mackenzie G.G., Queisser N., Wolfson M.L., Fraga C.G., Adamo A.M., Oteiza P.I. Curcumin induces cell-arrest and apoptosis in association with the inhibition of constitutively active NF-κB and STAT3 pathways in Hodgkin's lymphoma cells. Int J Cancer. 2008;123:56–65. doi: 10.1002/ijc.23477. [DOI] [PubMed] [Google Scholar]
- 82.Roberts A.B., Russo A., Felici A., Flanders K.C. Smad3: a key player in pathogenetic mechanisms dependent on TGF-β. Ann N Y Acad Sci. 2003;995:1–10. doi: 10.1111/j.1749-6632.2003.tb03205.x. [DOI] [PubMed] [Google Scholar]
- 83.Yao Q.Y., Xu B.L., Wang J.Y., Liu H.C., Zhang S.C., Tu C.T. Inhibition by curcumin of multiple sites of the transforming growth factor-beta 1 signaling pathway ameliorates the progression of liver fibrosis induced by carbon tetrachloride in rats. BMC Com Altern Med. 2012;12:156. doi: 10.1186/1472-6882-12-156. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 84.Liu G.T., Zhang T.M., Wang B.E., Wang Y.W. Protective action of seven natural phenolic compounds against peroxidative damage to biomembranes. Biochem Pharmacol. 1992;43:147–152. doi: 10.1016/0006-2952(92)90271-j. [DOI] [PubMed] [Google Scholar]
- 85.Gao H.Y., Li G.Y., Lou M.M., Li X.Y., Wei X.Y., Wang J.H. Hepatoprotective effect of matrine salvianolic acid B salt on carbon tetrachloride-induced hepatic fibrosis. J Inflam. 2012;9:16. doi: 10.1186/1476-9255-9-16. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 86.Tsai M.K., Lin Y.L., Huang Y.T. Effects of salvianolic acids on oxidative stress and hepatic fibrosis in rats. Toxicol Appl Pharmacol. 2009;242:155–164. doi: 10.1016/j.taap.2009.10.002. [DOI] [PubMed] [Google Scholar]
- 87.Basnet P., Yasuda I., Kumagai N. Inhibition of itch-scratch response by fruits of Cnidium monnieri in mice. Biol Pharmaceu Bull. 2001;24:1012–1015. doi: 10.1248/bpb.24.1012. [DOI] [PubMed] [Google Scholar]
- 88.Liu Y.W., Chiu Y.T., Fu S.L., Huang Y.T. Osthole ameliorates hepatic fibrosis and inhibits hepatic stellate cell activation. J Biomed Sci. 2015;22:63. doi: 10.1186/s12929-015-0168-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 89.López-Reyes A.G., Arroyo-Curras N., Cano B.G. Black bean extract ameliorates liver fibrosis in rats with CCl. Ann Hepatol. 2008;7:130–135. [PubMed] [Google Scholar]
- 90.Zhang S., Ji G., Liu J. Reversal of chemical-induced liver fibrosis in Wistar rats by puerarin. J Nutri Biochem. 2006;17:485–491. doi: 10.1016/j.jnutbio.2005.09.002. [DOI] [PubMed] [Google Scholar]
- 91.Liu C.Y., Gu Z.L., Zhou W.X., Guo C.Y. Effect of Astragalus complanatus flavonoid on anti-liver fibrosis in rats. World J Gastroenterol. 2005;11:5782. doi: 10.3748/wjg.v11.i37.5782. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 92.Sun W.Y., Wei W., Wu L., Gui S.Y., Wang H. Effects and mechanisms of extract from Paeonia lactiflora and Astragalus membranaceus on liver fibrosis induced by carbon tetrachloride in rats. J Ethnopharmacol. 2007;112:514–523. doi: 10.1016/j.jep.2007.04.005. [DOI] [PubMed] [Google Scholar]
- 93.Qin D., Wen Z., Nie Y., Yao G. Effect of Cichorium glandulosum extracts on CCl4-induced hepatic fibrosis. Iran Red Cres Med J. 2013:15. doi: 10.5812/ircmj.10908. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 94.Park E.J., Nan J.X., Kim J.Y. The ethanol-soluble part of a hot-water extract from Artemisia iwayomogi inhibits liver fibrosis induced by carbon tetrachloride in rats. J Pharm Pharmacol. 2000;52:875–881. doi: 10.1211/0022357001774561. [DOI] [PubMed] [Google Scholar]
- 95.Yuan L.P., Chen F.H., Ling L. Protective effects of total flavonoids of Bidens pilosa L. (TFB) on animal liver injury and liver fibrosis. J Ethnopharmacol. 2008;116:539–546. doi: 10.1016/j.jep.2008.01.010. [DOI] [PubMed] [Google Scholar]
- 96.Kadir F.A., Kassim N.M., Abdulla M.A., Yehye W.A. Hepatoprotective role of ethanolic extract of Vitex negundo in thioacetamide-induced liver fibrosis in male rats. Evid-Bas Comp Altern Med. 2013 doi: 10.1155/2013/739850. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 97.Wasser S., Ho J.M.S., Ang H.K., Tan C.E.L. Salvia miltiorrhiza reduces experimentally-induced hepatic fibrosis in rats. J Hepatol. 1998;29:760–771. doi: 10.1016/s0168-8278(98)80257-2. [DOI] [PubMed] [Google Scholar]
- 98.Nan J.X., Park E.J., Kim Y.C., Ko G., Sohn D.H. Scutellaria baicalensis inhibits liver fibrosis induced by bile duct ligation or carbon tetrachloride in rats. J Pharm Pharmacol. 2002;54:555–563. doi: 10.1211/0022357021778673. [DOI] [PubMed] [Google Scholar]
- 99.Wang J.H., Shin J.W., Choi M.K., Kim H.G., Son C.G. An herbal fruit, Amomum xanthoides, ameliorates thioacetamide-induced hepatic fibrosis in rat via antioxidative system. J Ethnopharmacol. 2011;135:344–350. doi: 10.1016/j.jep.2011.03.026. [DOI] [PubMed] [Google Scholar]
- 100.Motawi T.K., Hamed M.A., Shabana M.H., Hashem R.M., Naser A.F.A. Zingiber officinale acts as a nutraceutical agent against liver fibrosis. Nutr Metab. 2011;8:1. doi: 10.1186/1743-7075-8-40. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 101.Wu S.J., Lin Y.H., Chu C.C., Tsai Y.H., Chao J.C.J. Curcumin or Saikosaponin a improves hepatic antioxidant capacity and protects against CCl4-induced liver injury in rats. J Med Food. 2008;11:224–229. doi: 10.1089/jmf.2007.555. [DOI] [PubMed] [Google Scholar]
- 102.Ki S.H., Yang J.H., Ku S.K., Kim S.C., Kim Y.W., Cho I.J. Red ginseng extract protects against carbon tetrachloride-induced liver fibrosis. J Gins Res. 2013;37:45–53. doi: 10.5142/jgr.2013.37.45. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 103.Park W.H., Lee S.K., Kim C.H. A Korean herbal medicine, Panax notoginseng, prevents liver fibrosis and hepatic microvascular dysfunction in rats. Life Sci. 2005;76:1675–1690. doi: 10.1016/j.lfs.2004.07.030. [DOI] [PubMed] [Google Scholar]
- 104.Yen M.H., Weng T.C., Liu S.Y., Chai C.Y., Lin C.C. The hepatoprotective effect of Bupleurum kaoi, an endemic plant to Taiwan, against dimethylnitrosamine-induced hepatic fibrosis in rats. Biol Pharm Bull. 2005;28:442–448. doi: 10.1248/bpb.28.442. [DOI] [PubMed] [Google Scholar]
- 105.Luo Y.J., Yu J.P., Shi Z.H., Wang L. Ginkgo biloba extract reverses CCl4-induced liver fibrosis in rats. World J Gastroenterol. 2004;10:1037–1042. doi: 10.3748/wjg.v10.i7.1037. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 106.Hsieh C.C., Fang H.L., Lina W.C. Inhibitory effect of Solanum nigrum on thioacetamide-induced liver fibrosis in mice. J Ethnopharmacol. 2008;119:117–121. doi: 10.1016/j.jep.2008.06.002. [DOI] [PubMed] [Google Scholar]
- 107.Hsu Y.C., Chiu Y.T., Cheng C.C., Wu C.F., Lin Y.L., Huang Y.T. Antifibrotic effects of tetrandrine on hepatic stellate cells and rats with liver fibrosis. J Gastroenterol Hepatol. 2007;22:99–111. doi: 10.1111/j.1440-1746.2006.04361.x. [DOI] [PubMed] [Google Scholar]
- 108.Jin J.J., Zhong M., Yu S.M., Huang J.L. Effect of water extract of Cudrania cochinchinensis on liver fibrosis rat models induced by carbon tetrachloride. Chin J Exp Trad Med Formul. 2012;22:075. [Google Scholar]
- 109.Wang Y.P., Cheng M.L., Zhang B.F., Mu M., Wu J. Effects of blueberry on hepatic fibrosis and transcription factor Nrf2 in rats. World J Gastroenterol. 2010;16:2657–2663. doi: 10.3748/wjg.v16.i21.2657. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 110.Li L., Park D.H., Li Y.C. Anti-hepatofibrogenic effect of turnip water extract on thioacetamide-induced liver fibrosis. Lab Anim Res. 2010;26:1–6. [Google Scholar]
- 111.Lin W.C., Lin W.L. Ameliorative effect of Ganoderma lucidum on carbon tetrachloride-induced liver fibrosis in rats. World J Gastroenterol. 2006;12:265. doi: 10.3748/wjg.v12.i2.265. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 112.Wang H., Wu G., Park H.J. Protective effect of Phellinus linteus polysaccharide extracts against thioacetamide-induced liver fibrosis in rats: a proteomics analysis. Chin Med. 2012;7:1. doi: 10.1186/1749-8546-7-23. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 113.D'Argenio G., Amoruso D.C., Mazzone G. Garlic extract prevents CCl 4-induced liver fibrosis in rats: the role of tissue transglutaminase. Dig. Liv Dis. 2010;42:571–577. doi: 10.1016/j.dld.2009.11.002. [DOI] [PubMed] [Google Scholar]
- 114.Wills P.J., Asha V.V. Protective effect of Lygodium flexuosum (L.) Sw. extract against carbon tetrachloride-induced acute liver injury in rats. J Ethnopharmcol. 2006;108:320–326. doi: 10.1016/j.jep.2006.05.032. [DOI] [PubMed] [Google Scholar]
- 115.Chen X., Gao G., Luo W. Inhibitory effect of Dioscorea panthaica on CCl4-induced liver fibrosis in rats. J Med Pla Res. 2012;6:1532–1538. [Google Scholar]
- 116.Yoo S.H., Yoon C.J., Kim D.H. Anti-fibrotic effects of Rhus javanica Linn (Anacardiaceae) extract against Activated hepatic stellate cells via regulation of TGF-beta and smad signaling. Trop J Pharm Res. 2015;14:1413–1419. [Google Scholar]
- 117.Huang C., Ma T., Meng X. Potential protective effects of a traditional Chinese herb, Litsea coreana Levl., on liver fibrosis in rats. J Pharm Pharmacol. 2010;62:223–230. doi: 10.1211/jpp.62.02.0010. [DOI] [PubMed] [Google Scholar]
- 118.Abdel-Rahman M.K. Can apricot kernels fatty acids delay the atrophied hepatocytes from progression to fibrosis in dimethylnitrosamine (DMN)-induced liver injury in rats? Lipids Health Dis. 2011;10:114. doi: 10.1186/1476-511X-10-114. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 119.Toklu H.Z., Sehirli O., Sener G. Pomegranate peel extract prevents liver fibrosis in biliary-obstructed rats. J Phar Pharmacol. 2007;59:1287–1295. doi: 10.1211/jpp.59.9.0014. [DOI] [PubMed] [Google Scholar]
- 120.Liu J.Y., Chen C.C., Wang W.H., Hsu J.D., Yang M.Y., Wang C.J. The protective effects of Hibiscus sabdariffa extract on CCl4-induced liver fibrosis in rats. Food Chem Toxicol. 2006;44:336–343. doi: 10.1016/j.fct.2005.08.003. [DOI] [PubMed] [Google Scholar]
- 121.Hamza A.A. Ameliorative effects of Moringa oleifera Lam seed extract on liver fibrosis in rats. Food Chem Toxicol. 2010;48:345–355. doi: 10.1016/j.fct.2009.10.022. [DOI] [PubMed] [Google Scholar]
- 122.Türkdoğan M.K., Ozbek H., Yener Z., Tuncer I., Uygan I., Ceylan E. The role of Urtica dioica and Nigella sativa in the prevention of carbon tetrachloride-induced hepatotoxicity in rats. Phytoth Res. 2003;17:942–946. doi: 10.1002/ptr.1266. [DOI] [PubMed] [Google Scholar]
- 123.Amin A., Mahmoud-Ghoneim D. Zizyphusspina-christi protects against carbon tetrachloride-induced liver fibrosis in rats. Food Chem Toxicol. 2009;47:2111–2119. doi: 10.1016/j.fct.2009.05.038. [DOI] [PubMed] [Google Scholar]
- 124.Peng W.H., Tien Y.C., Huang C.Y. Fraxinus rhynchophylla ethanol extract attenuates carbon tetrachloride-induced liver fibrosis in rats via down-regulating the expressions of uPA, MMP-2, MMP-9 and TIMP-1. J Ethnopharmacol. 2010;127:606–613. doi: 10.1016/j.jep.2009.12.016. [DOI] [PubMed] [Google Scholar]
- 125.Hsu Y.W., Tsai C.F., Chang W.H., Ho Y.C., Chen W.K., Lu F.J. Protective effects of Dunaliella salina–A carotenoids-rich alga, against carbon tetrachloride-induced hepatotoxicity in mice. Food Chem Toxicol. 2008;46:3311–3317. doi: 10.1016/j.fct.2008.07.027. [DOI] [PubMed] [Google Scholar]
- 126.Li F.H., Liu P., Xiong W.G., Xu G.F. Effects of Cordyceps sinensis on dimethylnitrosamine-induced liver fibrosis in rats. J Chin Integ Med. 2006;4:514–517. doi: 10.3736/jcim20060515. [DOI] [PubMed] [Google Scholar]
- 127.Kim S.H., Cheon H.J., Yun N. Protective effect of a mixture of Aloe vera and Silybum marianum against carbon tetrachloride-induced acute hepatotoxicity and liver fibrosis. J Pharmacol Sci. 2009;109:119–127. doi: 10.1254/jphs.08189fp. [DOI] [PubMed] [Google Scholar]
- 128.Loguercio C., Andreone P., Brisc C. Silybin combined with phosphatidylcholine and vitamin E in patients with nonalcoholic fatty liver disease: a randomized controlled trial. Free Rad Biol Med. 2012;52:1658–1665. doi: 10.1016/j.freeradbiomed.2012.02.008. [DOI] [PubMed] [Google Scholar]
- 129.Song Y.N., Sun J.J., Lu Y.Y. Therapeutic efficacy of fuzheng-huayu tablet based traditional Chinese medicine syndrome differentiation on hepatitis-B-caused cirrhosis: a multicenter double-blind randomized controlled trail. Evid-Bas Com Altern Med. 2013 doi: 10.1155/2013/709305. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 130.Chen J., Gao W., Zhou P. Enhancement of hepatocyte differentiation from human embryonic stem cells by Chinese medicine Fuzhenghuayu. Sci. Report. 2016;6 doi: 10.1038/srep18841. [DOI] [PMC free article] [PubMed] [Google Scholar]